Short-term stock returns are largely driven by the perception of near-term earnings per share. Read more here.

Bailard Inc. drastically reduced its stake in Regeneron Pharmaceuticals, offloading 69.9% of its shares in the first quarter.

If you're looking for stocks that can make dramatic movements in a short time frame, the biotechnology space has what you ...

CWM LLC has more than doubled its stake in Regeneron Pharmaceuticals, snapping up an additional 2,007 shares to now hold a ...

In the latest trading session, Amgen (AMGN) closed at $294.76, marking a -1.17% move from the previous day. This change lagged the S&P 500's daily loss of 0.01%. Elsewhere, the Dow lost 0.32%, while ...

Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.

Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% gain. This was partly driven by its softer quarterly results and may have ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights.